相关实验视频
Updated: Jan 11, 2026

04:23
Application of Hemostatic Devices in Laparoscopic Hepatectomy
Published on: April 19, 2022
2.7K
在患有凝血病的妇科患者中使用局部静血剂
Alexis O'Connell1, Syeda Zainab Shah2
1HCA Florida Northwest Hospital, Margate, Florida.
HCA healthcare journal of medicine
|November 12, 2025
概括
局部止血剂在妇科手术中至关重要,特别是对于凝血病患者. 这一案例突出显示了在囊瘤切除过程中使用凝-胺剂所面临的挑战,并强调了有效血液静止的材料组成.
科学领域:
- 妇科外科手术 妇科外科
- 血液静止 血液静止 血液静止
- 血栓形成的管理
背景情况:
- 局部静血剂在手术中广泛用于控制出血.
- 它们在妇科手术中用于患有凝血病的患者的应用仍未得到充分研究.
- 患有深静脉血栓形成史的患者通常需要抗凝剂或化疗预防.
研究的目的:
- 为了说明在妇科手术中使用局部静血剂的考虑因素,用于化疗预防的患者.
- 在复杂的妇科手术中评估不同血静剂的疗效.
- 为了突显手术内并发症 (如囊切术) 对血静剂性能的影响.
主要方法:
- 一个62岁的女性病例介绍,她曾经患有深静脉血栓症,经历了完全的阴道切除术,阴道切割术和吊带安置.
- 结合凝-和基于凝的血静剂的内科使用.
- 在手术内进行囊切除和术后的阴道袖子血瘤的治疗.
主要成果:
- 患者经历了手术后出血,需要修复手术,原因是阴道袖子血液瘤.
- 应用了包括凝-胺在内的静血剂,以及输血血制品.
- 患者最终在手术干预后无事无事地恢复过来.
结论:
- 局部静血剂在接受化疗预防的妇科患者中需要仔细考虑.
- 材料成分影响静血剂的有效性,纤维素密封剂可能提供更快的作用.
- 囊切除并发症可能会破坏静血剂,由于靠近泌尿系统,影响其有效性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
271
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
271
Introduction to Hemostasis
13.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.2K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Venous Thrombosis IV: Nursing Management
190
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
190
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K

